Clinical Trial Results:
Gemtuzumab ozogamicin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61-75 years old with previously untreated AML: a randomized phase III trial (AML- 17) of the EORTC-LG and the GIMEMA-ALWP.
Summary
|
|
EudraCT number |
2005-001347-37 |
Trial protocol |
IT |
Global completion date |
13 Aug 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
23 Mar 2017
|
First version publication date |
23 Mar 2017
|
Other versions |
|
Summary report(s) |
06012_ShortReportAuthorities_20120907.pdf |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.